A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Assess the Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of LNP1892 (Monotherapy) in Chronic Kidney Disease (CKD) Patients with Secondary Hyperparathyroidism (SHPT), On Dialysis and Not on Dialysis

Trial Profile

A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Assess the Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of LNP1892 (Monotherapy) in Chronic Kidney Disease (CKD) Patients with Secondary Hyperparathyroidism (SHPT), On Dialysis and Not on Dialysis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs LNP 1892 (Primary)
  • Indications Secondary hyperparathyroidism
  • Focus Therapeutic Use
  • Sponsors Lupin
  • Most Recent Events

    • 13 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top